Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Dasatinib (Excl. Strength 100 Mg In Standard Sizes N2 And N3, Atc L01Ea02 For The Period 01.11.24 - 31.10.26

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 93422135

  Document Type - Tender Notices

Description - Description: Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for medicines dispensed at the expense of statutory health insurance companies. In view of the relev ant statutory provisions for the award of public contracts, DAK-Gesundheit carries out a regular process of active ingredient-related, formal tendering procedures in accordance with the provisions of Part 4 of the GWB. For medicines containing the above-mentioned active ingredient, dasatinib (only 100 mg strength in standard sizes N2 and N3), ATC L01EA02, which are to be specified by the bidder in Annex 2 to the contract, DAK-Gesundheit intends t

Gt Ref Id - 93422135

Deadline - Sep 05, 2026